Pmm2-CDG

2
Pipeline Programs
1
Companies
2
Clinical Trials
0
Approved Products

Pipeline by Development Stage

Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
2
0
0
0
Early DiscoveryClinical DevelopmentMarket

Competitive Landscape

1 companies ranked by most advanced pipeline stage

Glycomine
GlycomineCA - San Carlos
2 programs
2
GLM101Phase 21 trial
GLM101Phase 21 trial
Active Trials
NCT05549219CompletedEst. Nov 2025
NCT06657859Enrolling By InvitationEst. Oct 2029

Trial Timeline

Clinical trial activity over time

2022
2023
2024
2025
2026
2027
2028
2029
GlycomineGLM101
GlycomineGLM101

Clinical Trials (2)

Open-Label Extension Study to Assess GLM101 in PMM2-CDG Patients

Start: Sep 2024Est. completion: Oct 2029
Phase 2Enrolling By Invitation

24-Week Study to Assess the PD, Safety, Tolerability, and PK of GLM101 in Participants With PMM2-CDG

Start: Nov 2022Est. completion: Nov 2025
Phase 2Completed

Phase Legend

PreclinicalLab & animal studies
Phase 1Safety & dosing
Phase 2Efficacy testing
Phase 3Large-scale trials
On MarketApproved & available

Key Insights

1 companies competing in this space